EN
EN
| Pipeline | Product | Indication | Program | Progress |
|---|---|---|---|---|
|
E202
|
TCR-T
|
Cervical cancer
|
A phase I/II study of TC-E202 injection for relapsed or refractory cervical cancer
|
Recruiting
|
|
N201
|
TCR-T
|
synovial sarcoma, lung cancer, and other solid tumors
|
A phase I study of TC-N201 injection for relapsed or refractory solid tumor
|
Initiating
|
|
A103
|
CAR-T
|
Ovarian, Cervical, and endometrial cancer
|
A phase I study of TC-A103 injection for relapsed or refractory solid tumor
|
Recruiting
|
|
L200s
|
TCR-T
|
Extranodal NK/T cell Lymphoma
|
A phase Ib study of TC-L200s injection for relapsed or refractory ENKTL
|
Initiating
|
|
L200s
|
TCR-T
|
Nasopharynx cancer
|
A phase I study of TC-L200s injection for relapsed or refractory nasopharynx cancer
|
Recruiting
|
|
U101
|
NK
|
Solid tumor
|
A phase I study of TC-U101 injection for relapsed or refractory solid tumor
|
In preparation
|
|
H101
|
Peptide Vaccine
|
DIPG
|
A phase I study of peptide vaccine for relapsed or refractory DIPG
|
Recruiting
|
|
I301
|
CAR-T
|
Glioma
|
A phase I study of TC-I301 injection for relapsed or refractory glioma
|
In preparation
|
